Citigroup
KTTA icon

Citigroup’s Pasithea Therapeutics KTTA Stock Holding History

Citigroup’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-443
Closed -$319 – 6275
2025
Q3 		$319 Buy
+443
New +$324 ﹤0.01% 5739
2025
Q2 		– Sell
-13,706
Closed -$17.8K – 5793
2025
Q1 		$17.8K Buy
+13,706
New +$24.3K ﹤0.01% 5111

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Citigroup's KTTA Position: Q4 2025 in Review

Citigroup sold out of Pasithea Therapeutics (KTTA) in Q4 2025, closing a stake of 443 shares — an estimated $319 sold.

Citigroup first reported a position in KTTA in Q1 2025 and held it in 2 quarters. The position peaked at $17.8K in Q1 2025. 26 funds tracked by Wall St. Rank hold KTTA as of Q4 2025.

  • Citigroup reported no remaining Pasithea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 443 Pasithea Therapeutics shares in Q4 2025, an estimated $319.
  • Citigroup first reported a position in Pasithea Therapeutics in Q1 2025 and held it in 2 quarters.
  • Citigroup's Pasithea Therapeutics position peaked at $17.8K in Q1 2025.
  • 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.